Selected Publications
Susan M. Domchek, Alex Torres, Megan Aaron-Ocko, JoAnn Miller, Phil Seger, Hayley Knollman, Kim Reiss, Payal D. Shah, Matthew Morrow, Jeffrey Skolnik, Robert H. Vonderheide: Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations Oral Abstract Session, ASCO 2025, Chicago, IL : 2025.
Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss: LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes ASCO 2025, Chicago, IL : 2025.
Bever KM, Durham JN, Qi H, Azad NS, Laheru D, Fisher GA, Greten TF, Hays J, Krishnamurthy A, Reiss KA, Sanborn R, Wang H, Diaz LA, Le DT: 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors (KEYNOTE-016) Rapid Oral Abstract Session, ASCO 2025, Chicago, IL : 2025.
Kim A. Reiss, Katherine Nathanson, Alexa B. Schrock, Alexander D. Fine, Derek W. Brown, Brennan Decker, Jason Hughes, Chang Xu, Bahar Yilmazel, Rebecca Hodges, Kimberly Johnson, Amaya Gasco, Hanna Tukachinsky: BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC) ASCO 2025, Chicago IL : 2025.
Kim A. Reiss MD, Kevin C Soares MD, MS, Robert J Trophy MD, PhD, Bishal Gyawali, MD, PhD, FASCO: Treatment innovations in pancreatic cancer: putting patient priorities first ASCO Educational Book : 2025.
Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R.Pohman, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Sonawane, Sabrina Ceeraz DeLong, Melissa Christiano, Ramona F. Swaby, Sascha Abramson, Ken Locke, Debora Barton, Eugene Kennedy, Saar I. Gill, Daniel Cushing, Michael Klichinsky, Thomas Condamine, Yara Abdou: Chimeric antigen receptor macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1, first-in-human clinical trial Nature Medicine : 2025.
Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon Ahnert, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer NEJM : 2025.
Efrat Dotan, Paul J. Catalano, Leon Lenchik, Robert Boutin, Xin Yao, James Ohr, Kian-Huat Lim, George A. Fisher Jr., Namrata Vijayvergia, Sreenivasa R. Chandana, Aparna Kalyan, Richard F. Dunne, David B. Zhen, Daneng Li, Kim A. Reiss, Melissa A. Simon, Jordan Berlin, Lynne I. Wagner, Peter J. O'Dwyer: Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer ASCO GI, San Francisco, CA : 2025.
Vincent Chung, Katherine A. Guthrie, Michael J. Pishvaian, Andrew M. Lowy, Davendra Sohal, Kim Anna Reiss, Nina Niu Sanford, Carmen Allegra, Sarah Colby, Eileen M. O'Reilly, E. Gabriela Chiorean, Philip Agop Philip: Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752 ASCO GI, San Francisco, CA : 2025.
Celeste Simon, Xu Han, Michelle Burrows, Laura C Kim, Jimmy P Xu, Will Vostrejs, Van Le, Yangqing Jiang, Edna Cukierman, Ben Stanger, Clementina Mesaros, Brian Keith, Carson Poltorack, Kim Reiss, Sydney Shaffer: Cancer associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment Cell Reports : 2024.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-360-0735
Patient appointments: 800-789-7366